BDA-366 2mg 2mg | Purity Not Available
Adooq Bioscience
BDA-366 selectively inhibits BCL2, converting it to a cell death inducer.
More Information Supplier PageSearch Results
LY2857785 25mg 25mg | Purity Not Available
Adooq Bioscience
LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.
More Information Supplier PageLY2857785 5mg 5mg | Purity Not Available
Adooq Bioscience
LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.
More Information Supplier PageCB5083 5mg 5mg | Purity Not Available
Adooq Bioscience
CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models .
More Information Supplier PageCB5083 25mg 25mg | Purity Not Available
Adooq Bioscience
CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models .
More Information Supplier PageCB5083 10mg 10mg | Purity Not Available
Adooq Bioscience
CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models .
More Information Supplier PageACP-196 5mg 5mg | Purity Not Available
Adooq Bioscience
ACP-196 is an orally available inhibitor of Bruton??s tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.
More Information Supplier PageACP-196 25mg 25mg | Purity Not Available
Adooq Bioscience
ACP-196 is an orally available inhibitor of Bruton??s tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.
More Information Supplier PageACP-196 10mg 10mg | Purity Not Available
Adooq Bioscience
ACP-196 is an orally available inhibitor of Bruton??s tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.
More Information Supplier PageETC-1002 25mg 25mg | Purity Not Available
Adooq Bioscience
ETC-1002 is a novel, first-in-class, orally available, once-daily LDL-C lowering small molecule; activator of hepatic AMP-activated protein kinase (AMPK); also has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
More Information Supplier Page